CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 331 enrolled
Drug / intervention
Faster aspart +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04588259
NCT04588259Phase 3Completed

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Diabetes

Novo Nordisk A/S·interventional·Posted Oct 19, 2020·Updated Dec 4, 2025

In Brief

A Phase 3 clinical trial evaluating Faster aspart, Insulin aspart, and 1 other intervention for Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2. Completed, enrolled 331 participants across 40 sites in 2 countries.

Detailed Summary

Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine doctors can already prescribe). Participants will either get faster aspart or insulin aspart (NovoRapid®) - which treatment is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day: 3 injections 0-2 minutes before breakfast, lunch and dinner and 1 injection at the same time every day. All study medicines are provided in pens. A pen is a tool to inject insulin under the skin.The study will last for about 7 months (30 weeks). Participants will have 11 clinic visits and 17 phone contacts with the study doctor. At 8 clinic visits participants will have blood samples taken. At 3 clinic visits participants cannot eat or drink (water is allowed) 8 hours before the visits - at 2 of these visits participants will be asked to drink a liquid meal and to stay at the clinic for about 5 hours. Participants will fill in a diary the last 3 days before the visits/phone contacts. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, Hong Kong
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedOct 19, 2020
Enrollment StartOct 9, 2020
Primary CompletionJul 5, 2022
Study CompletionAug 5, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.7 years ago

Interventions

Faster aspartdrug

Administered s.c. (subcutaneously, under the skin) for 16 weeks

Insulin aspartdrug

Administered s.c. (subcutaneously, under the skin) for 16 weeks

Insulin degludecdrug

Administered s.c. (subcutaneously, under the skin) for 16 weeks